A phase 3 trial of cytisine as a smoking cessation aid

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cytisinicline (Primary) ; Nicotine replacement therapy
Indications Smoking withdrawal
Focus Therapeutic Use
Acronyms CASCAID

Most Recent Events

10 Aug 2017 According to an Achieve Life Sciences media release, this trial was conceived by Dr. Natalie Walker, National Institute for Health Innovation, University of Auckland and funded by the Health Research Council of New Zealand.
08 Mar 2017 According to an OncoGenex Pharmaceuticals media release, this trial was conducted by Dr. Walker.
28 Jul 2015 New trial record

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight